No, it will not go to $100 even if the drug works like a charm. You need to do the math on what that would imply for market value and then revisit your assumption. As of the last 10Q, there were 448 million shares outstanding, and 367 million warrants that would be exercised. Subsequent events add about another 4 million so in total there are at least 820 million shares on a fully diluted basis. Jerry keeps better track of the count than I do.
At $100 per share, you are valuing a single-drug company at $82 billion even though you acknowledge that it may take another decade of investment to get there. Certainly there are pharma companies that command such market caps (Pfizer is about $250 billion, Novartis is $190 billion) but none of them got anywhere close to an eleven digit value on a single drug.
It is OK to dream about the potential returns on a twenty cent investment, but you need to crank the numbers too.